CSL (CMXHF) Inventories, Raw Materials & Components : $0 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is CSL Inventories, Raw Materials & Components?

CSL's inventories, raw materials & components for the quarter that ended in Dec. 2023 was $0 Mil.

CSL's quarterly raw materials increased from Dec. 2022 ($0 Mil) to Jun. 2023 ($1,592 Mil) but then declined from Jun. 2023 ($1,592 Mil) to Dec. 2023 ($0 Mil).

CSL's annual raw materials increased from Jun. 2021 ($1,309 Mil) to Jun. 2022 ($1,515 Mil) and increased from Jun. 2022 ($1,515 Mil) to Jun. 2023 ($1,592 Mil).

CSL Inventories, Raw Materials & Components Historical Data

The historical data trend for CSL's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Inventories, Raw Materials & Components Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

915.20

876.80

1,309.10

1,515.20

1,592.00

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															-	1,515.20	-	1,592.00	-

CSL Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

CSL (CMXHF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.